Silicosis Clinical Trial
Official title:
An Open, Randomised, Controlled and Unicenter Clinical Trial to Assess the Efficiency of Pirfenidone for the Reduction of Pulmonary Metabolic, Inflammatory and Fibrogenic Activity in Patients With Silicosis Due to Artificial Stone and PMF
Silicosis is one of the leading causes of occupational respiratory disease worldwide. It is due to inhalation of respirable crystalline silica and can lead to progressive massive fibrosis (PMF), respiratory failure, and death. It is estimated that it causes more than 10,000 deaths a year worldwide, mainly in developing countries, although the level of underdiagnosis is high. In developed countries the incidence of the disease has been progressively decreasing in recent years, mainly due to the implementation of effective prevention measures, better occupational health surveillance systems and the displacement of mining activity to other countries, in a way that in the United Kingdom 216 cases were reported from 1996 to 2017. At the moment, there is no curative treatment for the disease, and the only therapeutic option is lung transplantation (when the disease evolves to PMF and subsequent respiratory failure). Meanwhile, the only accepted treatment is supportive treatment, with the administration of oxygen therapy in case of respiratory failure, early treatment of respiratory infections, vaccinations and respiratory rehabilitation. In recent years, molecules with antifibrogenic capacity have been developed and have demonstrated their ability to decrease pulmonary fibrogenic activity in diseases such as Idiopathic Pulmonary Fibrosis (IPF). This has been a milestone in the treatment of this disease and, therefore, its possible application to other diseases that share fibrogenic mechanisms with IPF, as PMF. The two molecules with the most clinical experience and approved for IPF are nintedanib and pirfenidone. The antifibrotic properties of pirfenidone have raised great expectations and many clinical trials are currently being carried out in other lung diseases that cause fibrosis, that is why we decide to study the efficacy of pirfenidone in reducing metabolic, inflammatory, and fibrogenic lung disease in patients with artificial stone silicosis and progressive massive fibrosis (PMF).
Status | Recruiting |
Enrollment | 18 |
Est. completion date | November 15, 2023 |
Est. primary completion date | November 15, 2022 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 1. Age over 18 years and under 65. - 2. Man with a diagnosis of silicosis in the form of PMF by lung or lymph node biopsy, or by radiological criteria. - 3. History of exposure to silica in work with artificial stone for at least 5 years. - 4. Patients capable of consenting to their participation in the study by providing written informed consent, or, if they are not trained, through a legal repressentative. Exclusion Criteria: - 1. Participation in another clinical trial in the 6 months prior to the start of participation in this study. - 2. Hypersensitivity to any of the components of pirfenidone. - 3. Biological or farmacological treatment for any other disease or condition related to silicosis or PMF. Exception: prednisona (or equivalent) dose 20mg per day or lower. - 4. Concomitant treatment with a drug that can causes pirfenidone interactions: Cytotoxic drugs, immunosuppressants, cytokine modulators including but not limited to azathioprine, bosentan, ambrisentan, cyclophosphramide, cyclosporine, etarnecept, iloprost, infliximab, leukotriene antagonists, methotrexate, mycophenolate , tacrolimus, montelukast, tetrathiomolybdate, TNF-alpha inhibitors, imatinib mesylate, interferon gamma 1-beta, and tyrosine kinase inhibitors. Strong CYP1A2 inhibitors (eg fluvoxamine, enoxacin), P-glycoprotein or CYP3A4 inhibitors (eg Ketoconazole, erythromycin), or their inducers (eg rifampicin, carbamazepine, phenytoin). Other moderate CYP1A2 inhibitors (eg amiodarone or propafenone) which will also be prohibited. Any investigational therapy in an active clinical trial. Grapefruit juice. - 5. Active infectious disease. - 6. Any pathology that may condition the evolution of respiratory diseases, including cancer, HIV, HBV, HCV, liver cirrhosis, liver failure, severe kidney failure or any other that in the opinion of the investigator may interfere with the results of the study. - 7. Active smoking. - 8. Laboratory test abnormalities at screening timepoint - Total bilirrubin >2 ULN - AST/SGOT or ALT/SGPT > 2.5 ULN - Alkaline phosphatase >3.0 ULN - Creatinine clearance <40 mL/min (Cockcroft-Gault). - 9. Concomitant treatments that may cause serious digestive events. - 10. Digestive surgery or similar procedures that may cause digestive intolerances. - 11. Not availability to complete all the trial visits. - 12. Angiodema |
Country | Name | City | State |
---|---|---|---|
Spain | Antonio León Jiménez | Cadiz |
Lead Sponsor | Collaborator |
---|---|
Instituto de investigación e innovación biomédica de Cádiz |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Metabolic pulmonary activity assessed by PET-CT Scan (18 FFDG) | Metabolic pulmonary activity assessed by PET-CT Scan (18 FFDG) in patients treated with pirfenidone vs control patients. The variables will be analyzed in lung and mediastinum independently and the measurement of the metabolic response will be based on the standardized uptake value (SUV) at its maximum (SUVmax) and mean (SUVmean) values. | baseline (day 1), month 6, month 12 | |
Secondary | Cell biomarkers in peripheral blood: - Pro/anti fibrotic and pro/anti inflammatory biomarkers | Pro/anti fibrotic and pro/anti inflammatory biomarkers: cytokines (IL-1a, IL-1ß, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IL-18, IP-10, TGF-ß, TNF-a, IFN-?, MIP-1a, MIP-1ß, MCP-1, PDGF, bFGF, MMP1, -2, -7, -9, -10). Immunological biomarkers: CD45, CD45RO, CD45RA, CD3, CD4, CD8, CD19, CD27, CD56, CD126, CD25, INF-?, IL-4, FoxP3, CD196 y CD161 Note: There are no previous studies in patients with artificial stone silicosis in which they have analyzed the indicated biomarkers. This is a comprehensive preliminary analysis of biomarkers and we want to correlate the obtained values with the results derived from PET-CT in both groups of patients in the trial. | baseline (day 1), month 3, month 6, month 9, month 12 | |
Secondary | Number of adverse events (AE) and adverse reactions (AR), of serious adverse events (SAE) and serious and unexpected adverse reactions (SUSAR). | Number of adverse events (AE) and adverse reactions (AR), of serious adverse events (SAE) and serious and unexpected adverse reactions (SUSAR). | baseline (day 1), month 3, month 6, month 9, month 12 | |
Secondary | Respiratory symptoms (cough, expectoration and dyspnea) and quality of life related to health using the EQ-5D 5L test. | Respiratory symptoms (cough, expectoration and dyspnea) and quality of life related to health using the EQ-5D 5L test. | baseline (day 1), month 3, month 6, month 9, month 12 | |
Secondary | Respiratory function variables | Forced Vital Capacity (FVC), Forced Expiratory Volume in the first second, ratio Forced Expiratory in the first second / Forced Vital Capacity and Diffusing Capacity of the lungs for carbon monoxide, obtained through standardized respiratory function tests. | baseline (day 1), month 3, month 6, month 9 and month 12 | |
Secondary | Radiological categorization by chest radiology and by High Resolution Computed Tomography, following the International Classification of High-resolution Computed Tomography for Occupational and Environmental Respiratory Diseases (ICOERD) | Radiological categorization by chest radiology and by High Resolution Computed Tomography, following the International Classification of High-resolution Computed Tomography for Occupational and Environmental Respiratory Diseases (ICOERD) | baseline (day 1), month 6, month 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT01338064 -
Oxidative Stress Biomarkers to Monitor and Early Detect Health Impairment in Workers Exposed to Silica (Caesar Stone)
|
N/A | |
Not yet recruiting |
NCT01329003 -
DNA-damage Pathways in Workers Exposed to Silica (Caesar Stone)
|
N/A | |
Recruiting |
NCT04161014 -
The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial
|
Phase 2 | |
Completed |
NCT02430259 -
Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention
|
Phase 3 | |
Recruiting |
NCT06403800 -
Silicosis and Silicotuberculosis Among Small Scale Gemstone Miners in Northern Tanzania
|
||
Not yet recruiting |
NCT06011785 -
Using Silica 12CH to Mitigate the Effects and Symptoms of Silicosis in Brazil
|
Early Phase 1 | |
Not yet recruiting |
NCT05402176 -
The SHIELD Whole Lung Lavage Study
|
||
Completed |
NCT02794701 -
Comprehensive Risk Assessment of People With Silicosis: A Population-based Study
|
||
Completed |
NCT01977131 -
Safety Study of Autologous Bone Marrow Stromal Cells With Modification by Hepatocyte Growth Factor to Treat Silicosis
|
Phase 1/Phase 2 | |
Completed |
NCT00005280 -
Specialized Center of Research in Occupational and Immunologic Lung Disease
|
N/A | |
Recruiting |
NCT05538299 -
Silicosis Treatment, Action, Screening and Surveillance in Rwanda Trials
|
||
Completed |
NCT01725971 -
Oscillation Mechanics of the Respiratory System in Never-smoking Patients With Silicosis
|
N/A | |
Recruiting |
NCT06090370 -
Reducing Silica Exposure Among Brick Kiln Workers in Nepal
|
N/A | |
Completed |
NCT04205708 -
Screening Strategy for Early Diagnosis of Silicosis in At-Risk Populations in Oklahoma
|
||
Recruiting |
NCT05546944 -
The SHIELD Study-silicosis
|